Table 2.

Clinical Effectiveness of Abatacept in non-bionaive and ABA-bionaive patients.

Non-Bionaive Patients
Response variable	6 months		12 months
	N	%	N	%
EULAR response
Satisfactory	36	34.29	43	46.74
Unsatisfactory	69	65.71	49	53.26
Remission (DAS28 < 2.6)	18	17.14	28	30.43
LDA (2.6 ≥ DAS28 ≥ 3.2)	22	20.95	20	21.74
ABA-Bionaive Patients
Response variable		6 months		12 months
	N	%	N	%
EULAR response
Satisfactory	8	53.33	11	78.57
Unsatisfactory	7	46.67	3	21.43
Remission (DAS28 < 2.6)	3	20	9	64.29
LDA (2.6 ≥ DAS28 ≥ 3.2)	5	33.33	3	21.43

ABA, abatacept; EULAR, European League Against Rheumatism; LDA, Low-activity disease.